Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Hao Chen

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5134028085. Sources: OpenAlex.

Their work

Papers
37 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 4 papers · 2017: 1 paper · 2018: 3 papers · 2019: 5 papers · 2020: 4 papers · 2021: 6 papers · 2022: 5 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 37

  1. ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41421-026-00882-9↗
  2. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Last author DOI 10.1007/s00262-023-03438-y↗
  3. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Last author DOI 10.1186/s12967-023-04702-6↗
  4. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Last author DOI 10.1002/ctm2.1126↗
  5. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating P… Co-author DOI 10.1002/ctm2.654↗
  6. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  7. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  8. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  9. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  10. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients. Co-author DOI 10.1186/s12885-021-09056-0↗
  11. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Co-author DOI 10.1186/s13046-021-02097-0↗
  12. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. Last author DOI 10.18632/aging.202264↗
  13. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.682261↗
  14. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.634881↗
  15. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  16. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02527-1↗
  17. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Co-author DOI 10.21037/jgo.2020.03.02↗
  18. The Necessity of Dissection of No. 14 Lymph Nodes to Patients With Pancreatic Ductal Adenocarcinoma Based on the Embryonic Development of the Head of the Pancr… Co-author DOI 10.3389/fonc.2020.01343↗
  19. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. Last author DOI 10.1002/jcb.28457↗
  20. Corrigendum to "GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer" [Cancer Le… Co-author DOI 10.1016/j.canlet.2019.03.031↗
  21. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2019.03.005↗
  22. The LIM protein Ajuba/SP1 complex forms a feed forward loop to induce SP1 target genes and promote pancreatic cancer cell proliferation. Co-author DOI 10.1186/s13046-019-1203-2↗
  23. Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEE… Co-author DOI 10.3389/fonc.2019.01386↗
  24. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… Co-author DOI 10.1002/jcb.26270↗
  25. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. Last author DOI 10.1016/j.canlet.2017.09.044↗
  26. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  27. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  28. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.06.016↗
  29. TMEM45B promotes proliferation, invasion and migration and inhibits apoptosis in pancreatic cancer cells. Co-author DOI 10.1039/c6mb00203j↗
  30. Long noncoding RNA uc.345 promotes tumorigenesis of pancreatic cancer by upregulation of hnRNPL expression. Last author DOI 10.18632/oncotarget.12253↗
  31. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7375↗
  32. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.4167↗
  33. The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. Co-author DOI 10.3109/07357907.2015.1025794↗
  34. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-14-0181↗
  35. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2126↗
  36. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Co-author DOI 10.1007/s00441-013-1711-x↗
  37. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-013-0903-z↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 27 shared papers, 2013–2023 · strength 2.33
  2. Chenghong Peng · 25 shared papers, 2013–2022 · strength 2.02
  3. Xiaxing Deng · 18 shared papers, 2013–2022 · strength 1.55
  4. Lingxi Jiang · 8 shared papers, 2020–2023 · strength 1.10
  5. Youwei Zhu · 8 shared papers, 2018–2023 · strength 0.97
  6. Qian Zhan · 11 shared papers, 2013–2022 · strength 0.83
  7. Lijie Han · 5 shared papers, 2022–2026 · strength 0.83
  8. Xiongxiong Lu · 9 shared papers, 2013–2022 · strength 0.66
  9. Chenlei Wen · 7 shared papers, 2016–2022 · strength 0.65
  10. Jiewei Lin · 5 shared papers, 2019–2022 · strength 0.63
  11. Cheng Xiong · 4 shared papers, 2021–2023 · strength 0.60
  12. Meilin Xue · 4 shared papers, 2021–2023 · strength 0.60
  13. Jiangning Gu · 8 shared papers, 2015–2020 · strength 0.59
  14. Siyi Zou · 5 shared papers, 2019–2022 · strength 0.59
  15. Xiaxing Deng · 7 shared papers, 2013–2022 · strength 0.55
  16. Dongfeng Cheng · 6 shared papers, 2018–2021 · strength 0.54
  17. Yongsheng Jiang · 3 shared papers, 2021–2023 · strength 0.43
  18. Jiabin Jin · 6 shared papers, 2013–2021 · strength 0.42
  19. Gang Wei · 5 shared papers, 2016–2022 · strength 0.41
  20. Kai Qin · 3 shared papers, 2021–2022 · strength 0.41
  21. Yizhi Cao · 3 shared papers, 2022 · strength 0.39
  22. Zengyu Feng · 3 shared papers, 2020–2022 · strength 0.38
  23. Kexian Li · 3 shared papers, 2020–2022 · strength 0.38
  24. Hongzhe Li · 4 shared papers, 2017–2022 · strength 0.38
  25. Baiyong Shen · 3 shared papers, 2016–2023 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.